Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

News Focus

LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Algernon Announces Closing of $2.07 Million Prospectus Offering of Units

GlobeNewswire November 1, 2019

IIROC Trade Resumption - AGN

Canada NewsWire October 25, 2019

Algernon Announces Pricing and Filing of Amended and Restated Prospectus

GlobeNewswire October 25, 2019

IIROC Trading Halt - AGN

Canada NewsWire October 25, 2019

Algernon Files Final Short Form Prospectus

Stockhouse Editorial October 2, 2019

Algernon Pharmaceuticals Announces Filing of a Final Short Form Prospectus

GlobeNewswire October 2, 2019

Algernon Announces Prospectus Offering Pricing

Stockhouse Editorial September 6, 2019

Algernon Announces Pricing of Prospectus Offering

GlobeNewswire September 6, 2019

Algernon Pharmaceuticals Announces Emoxypine (NP-178), a Top Selling Drug in Russia, as its Lead Drug for Inflammatory Bowel Disease

GlobeNewswire August 2, 2019

Algernon Announces Lead Drug for IBD

Stockhouse Editorial August 2, 2019

Algernon Reports Russian Performance Enhancing Drugs Outperform in NASH and CKD Studies

Stockhouse Editorial August 1, 2019

Algernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) Exhibited Potent Anti-Fibrotic Activity in NASH and CKD Studies

GlobeNewswire July 31, 2019

Report: Key Algernon Compound Cuts Lung Fibrosis in Half

Stockhouse Editorial July 29, 2019

Algernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis in a Recent Idiopathic Pulmonary Fibrosis Study by 56%

GlobeNewswire July 29, 2019

Algernon Pharmaceuticals Announces Short Form Prospectus Unit Offering

GlobeNewswire July 4, 2019

Algernon Pharma Lung Treatment Outperforms Industry Standard

Stockhouse Editorial July 3, 2019

Algernon Pharmaceuticals' NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56% Outperforming USFDA Approved Treatments Nintedanib and Pirfenidone

GlobeNewswire July 3, 2019

Taking Unparalleled Results to Treat the Next Epidemic

Stockhouse Editorial May 22, 2019

Algernon Pharmaceuticals Appoints Leading Inflammatory Bowel Disease Expert Dr. Walter Reinisch to Its Medical and Scientific Advisory Board

GlobeNewswire April 4, 2019

Algernon Pharma’s Lead NASH Compound Shows Fibrosis Reduction

Stockhouse Editorial April 1, 2019